{"title":"Novel approaches to the management of hyperlipidaemia","authors":"Anna Kate Barton","doi":"10.1002/psb.2093","DOIUrl":null,"url":null,"abstract":"A range of novel lipid‐lowering agents are now available, providing options for patients unable to achieve sufficient control on older drugs such as statins. This article gives an overview of the main lipid‐lowering agents, their indications and usage, with a focus on the newer therapies targeting PCSK9.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A range of novel lipid‐lowering agents are now available, providing options for patients unable to achieve sufficient control on older drugs such as statins. This article gives an overview of the main lipid‐lowering agents, their indications and usage, with a focus on the newer therapies targeting PCSK9.